No Deal

The BIA is clear that the UK crashing out of the EU with 'no deal' must be avoided. A cliff-edge 'no deal' Brexit will negatively impact patients, public health and the life sciences sector. The UK and EU reaching a deal significantly improves the chance of stability and increased certainty for business. The UK’s life sciences industry has already endured considerable disruption, duplication and uncertainty, and it’s likely this will continue to be the case for the months ahead.


To see ‘no deal’ information from earlier this year please follow this link.

JULY 2019

Medicines and medical supplies: continuity of supply update

BIA Response to 'medicines and medical supplies: continuity of supply update'


MARCH 2019

Office for Life Sciences - Collated Guidance for Business on No Deal Preparations

This letter provides information on MHRA guidance, Life Sciences guidance, Import and Export guidance as well as guidance for UK Nationals Living and Travelling to and from the EU.  

MHRA Update on EU Exit - Including Guidance on Operational Changes 

Please find attached a list of the guidance that will be issued in the weeks up to and including 29 March, including their target date for publication (guidance will be published sooner where possible, but this is designed to give you an idea of what to expect when). This guidance is intended to be enacted in the event of a no-deal.


Changes to SPC and Patent Law if the UK Leaves the EU Without a Deal 

If the UK leaves the EU without a deal, the Patents (Amendment) (EU Exit) Regulations 2019 (“the Patents Regulations”) will enter into force on exit day. Under the European Union (Withdrawal) Act 2018, EU law relating to patents will be retained in UK law at that time. These regulations ensure that the retained law makes sense and continues to work as UK law outside the EU. To read more please follow this link.